[go: up one dir, main page]

WO2008141282A3 - Matériaux et procédés pour la suppression de tumeurs grâce à la foxp3 - Google Patents

Matériaux et procédés pour la suppression de tumeurs grâce à la foxp3 Download PDF

Info

Publication number
WO2008141282A3
WO2008141282A3 PCT/US2008/063419 US2008063419W WO2008141282A3 WO 2008141282 A3 WO2008141282 A3 WO 2008141282A3 US 2008063419 W US2008063419 W US 2008063419W WO 2008141282 A3 WO2008141282 A3 WO 2008141282A3
Authority
WO
WIPO (PCT)
Prior art keywords
f0xp3
protein
methods
expression
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/063419
Other languages
English (en)
Other versions
WO2008141282A2 (fr
Inventor
Yan Liu
Pan Zheng
Xing Chang
Lizhong Wang
Runhua Liu
Yin Wang
Yang Liu
Tao Zuo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
University of Michigan Ann Arbor
Ohio State University Research Foundation
Original Assignee
University of Michigan System
University of Michigan Ann Arbor
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System, University of Michigan Ann Arbor, Ohio State University Research Foundation filed Critical University of Michigan System
Publication of WO2008141282A2 publication Critical patent/WO2008141282A2/fr
Publication of WO2008141282A3 publication Critical patent/WO2008141282A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des procédés de traitement d'un cancer chez un sujet comprenant l'administration d'une protéine F0XP3, d'un acide nucléique codant une protéine F0XP3, ou d'un composé d'induction qui induit l'expression de la protéine FOXP3. Des procédés de changement d'un phénotype d'une cellule cancéreuse ou d'une cellule tumorale, des procédés d'inhibition de croissance de telles cellules, et des procédés d'induction de l'apoptose dans ces cellules sont également fournis. Ces procédés comprennent la mise en contact de la cellule avec une protéine F0XP3, un acide nucléique codant pour une protéine F0XP3, ou le composé d'induction qui induit l'expression de la protéine F0XP3. Des procédés de diagnostic, comprenant la comparaison de l'expression, ou de la structure, d'une protéine F0XP3 ou d'un gène F0XP3 dans un échantillon d'essai à celle d'un échantillon normal ou antérieur sont en outre fournis. Un procédé de dépistage de l'activité anticancéreuse d'un composé d'essai, comprenant l'administration du composé d'essai à des cellules et la mesure de la protéine F0XP3 ou de l'expression génique de F0XP3 est également fourni.
PCT/US2008/063419 2007-05-11 2008-05-12 Matériaux et procédés pour la suppression de tumeurs grâce à la foxp3 Ceased WO2008141282A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91748807P 2007-05-11 2007-05-11
US60/917,488 2007-05-11

Publications (2)

Publication Number Publication Date
WO2008141282A2 WO2008141282A2 (fr) 2008-11-20
WO2008141282A3 true WO2008141282A3 (fr) 2009-04-02

Family

ID=40002875

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/063419 Ceased WO2008141282A2 (fr) 2007-05-11 2008-05-12 Matériaux et procédés pour la suppression de tumeurs grâce à la foxp3

Country Status (2)

Country Link
US (1) US8158596B2 (fr)
WO (1) WO2008141282A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10131953B2 (en) * 2011-11-03 2018-11-20 Wisconsin Alumni Research Foundation Unbiased DNA methylation markers define an extensive field defect in histologically normal prostate tissues associated with prostate cancer: new biomarkers for men with prostate cancer
CN102603892B (zh) * 2012-02-22 2013-10-30 尉军 一种肿瘤标志物foxp3抗原多肽及应用
WO2013151490A1 (fr) 2012-04-02 2013-10-10 John Andersson Méthodes et composés pour le traitement de maladies
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
DK2850186T3 (en) 2012-05-16 2019-04-08 Translate Bio Ma Inc COMPOSITIONS AND PROCEDURES FOR MODULATING SMN GENFAMILY EXPRESSION
CA2873797A1 (fr) 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions et methodes pour moduler l'expression de utrn
BR112014028631A2 (pt) 2012-05-16 2017-10-17 Rana Therapeutics Inc composições e métodos para modulação da expressão da família de genes da hemoglobina
CA2873779A1 (fr) 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions et methodes pour moduler l'expression de mecp2
AU2013262699A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating ATP2A2 expression
TWI454698B (zh) * 2012-05-22 2014-10-01 Glory Biomedical Co Ltd 用於檢測腫瘤發生之腫瘤標誌、方法與套組
AU2014274730A1 (en) * 2013-06-07 2016-01-21 Rana Therapeutics, Inc. Compositions and methods for modulating FOXP3 expression
CA2921459A1 (fr) 2013-08-16 2015-02-19 Rana Therapeutics, Inc. Oligonucleotides ciblant des regions de l'euchromatine de genes
WO2016138213A1 (fr) * 2015-02-25 2016-09-01 Kiromic, Llc Compositions et procédés pour traiter des maladies cardiovasculaires à l'aide de foxp3
KR101971860B1 (ko) * 2016-01-25 2019-04-26 부산대학교 산학협력단 리보솜 불활성화를 통한 중합체 면역글로불린 수용체 단백질의 발현 조절 방법
WO2017181026A1 (fr) * 2016-04-15 2017-10-19 Translate Bio Ma, Inc. Modulation sélective de l'expression de foxp3
GB201617470D0 (en) * 2016-10-14 2016-11-30 Linnane Pharma Ab Novel therapy
EP4644554A2 (fr) * 2016-10-31 2025-11-05 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Procédé de traitement d'une maladie auto-immune à l'aide de lymphocytes t cd4 avec stabilisation modifiée de l'expression du gène foxp3 endogène
WO2019040655A1 (fr) * 2017-08-22 2019-02-28 The Regents Of The University Of California Vecteurs lentiviraux exprimant foxp3 dans des cellules souches hématopoïétiques pour traiter des déficiences de l'immunité et des maladies auto-immunes
SG11202007878UA (en) 2018-04-27 2020-09-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Expression of foxp3 in edited cd34+ cells
WO2019234221A1 (fr) 2018-06-08 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de stratification et de traitement d'un patient souffrant de leucémie lymphoïde chronique
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0612728A2 (fr) * 1993-02-15 1994-08-31 Ajinomoto Co., Inc. Dérivés d'anisomycine et les agents anticancéreux, antifungicides et antiprotozoaires les contenant
US20030170648A1 (en) * 2001-05-08 2003-09-11 Darwin Molecular Corporation Method for regulating immune function in primates using the Foxp3 protein
WO2004022104A2 (fr) * 2002-09-06 2004-03-18 Isis Innovation Ltd. Foxp2 et ses utilisations
WO2006138478A2 (fr) * 2005-06-17 2006-12-28 The Trustees Of The University Of Pennylvania Stimulation de recepteurs de type toll sur des lymphocytes t

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0612728A2 (fr) * 1993-02-15 1994-08-31 Ajinomoto Co., Inc. Dérivés d'anisomycine et les agents anticancéreux, antifungicides et antiprotozoaires les contenant
US20030170648A1 (en) * 2001-05-08 2003-09-11 Darwin Molecular Corporation Method for regulating immune function in primates using the Foxp3 protein
WO2004022104A2 (fr) * 2002-09-06 2004-03-18 Isis Innovation Ltd. Foxp2 et ses utilisations
WO2006138478A2 (fr) * 2005-06-17 2006-12-28 The Trustees Of The University Of Pennylvania Stimulation de recepteurs de type toll sur des lymphocytes t

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BANHAM AH ET AL: "FOXP1 a novel candidate tumor suppressor gene on chromosome 3p", CANCER DETECTION AND PREVENTION, XX, XX, 1 October 2000 (2000-10-01), pages 1, XP002163656, ISSN: 0361-090X *
BENNETT C L ET AL: "The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3.", NATURE GENETICS JAN 2001, vol. 27, no. 1, January 2001 (2001-01-01), pages 20 - 21, XP002511266, ISSN: 1061-4036 *
BOVENZI V ET AL: "Antineoplastic action of 5-aza-2'-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells.", CANCER CHEMOTHERAPY AND PHARMACOLOGY JUL 2001, vol. 48, no. 1, July 2001 (2001-07-01), pages 71 - 76, XP009025926, ISSN: 0344-5704 *
BRUNKOW M E ET AL: "Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse.", NATURE GENETICS JAN 2001, vol. 27, no. 1, January 2001 (2001-01-01), pages 68 - 73, XP002226810, ISSN: 1061-4036 *
GUPTA S ET AL: "Expression of FOXP3 and vascular endothelial growth factor in human breast cancer: its correlation with angiogenesis and disease progression", EJC SUPPLEMENTS, vol. 4, no. 2, March 2006 (2006-03-01), & 5TH EUROPEAN BREAST CANCER CONFERENCE; NICE, FRANCE; MARCH 21 -25, 2006, pages 126, XP024988958, ISSN: 1359-6349 *
KATOH M ET AL: "HUMAN FOX GENE FAMILY (REVIEW)", INTERNATIONAL JOURNAL OF ONCOLOGY, DEMETRIOS A. SPANDIDOS ED. & PUB, GR, vol. 25, no. 5, 1 November 2004 (2004-11-01), pages 1495 - 1500, XP009049979, ISSN: 1019-6439 *
MASTRANGELO M J ET AL: "A phase I study of emetine hydrochloride (NSC 33669) in solid tumors.", CANCER MAY 1973, vol. 31, no. 5, May 1973 (1973-05-01), pages 1170 - 1175, XP002511263, ISSN: 0008-543X *
ZUO TAO ET AL: "FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2.", THE JOURNAL OF CLINICAL INVESTIGATION DEC 2007, vol. 117, no. 12, December 2007 (2007-12-01), pages 3765 - 3773, XP002511265, ISSN: 0021-9738 *
ZUO TAO ET AL: "FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene.", CELL 29 JUN 2007, vol. 129, no. 7, 29 June 2007 (2007-06-29), pages 1275 - 1286, XP002511264, ISSN: 0092-8674 *

Also Published As

Publication number Publication date
WO2008141282A2 (fr) 2008-11-20
US8158596B2 (en) 2012-04-17
US20090325868A1 (en) 2009-12-31

Similar Documents

Publication Publication Date Title
WO2008141282A3 (fr) Matériaux et procédés pour la suppression de tumeurs grâce à la foxp3
NZ621733A (en) Lung cancer biomarkers and uses thereof
HK1199068A1 (en) Identification of gene expression profile as a predictive biomarker for lkb1 status
Hernandez et al. Glioblastoma: relationship between metabolism and immunosuppressive microenvironment
Fan et al. Over expression of PPP2R2C inhibits human glioma cells growth through the suppression of mTOR pathway
WO2012103031A3 (fr) Détection d'anomalies génétiques
WO2012162660A3 (fr) Procédés faisant appel à la méthylation de l'adn pour identifier une cellule ou un mélange de cellules afin de pronostiquer et de diagnostiquer des maladies et pour effectuer des traitements de réparation cellulaire
WO2011047033A3 (fr) Biomarqueur d'identification de cellules tumorales de mélanome
WO2011087709A3 (fr) Translocations d'eml4-alk dans le cancer pulmonaire
WO2009017655A3 (fr) Procédés et compositions pour stimuler la prolifération ou la différenciation de cellules souches par la substance p ou un analogue de celle-ci
Albury et al. Constitutively active Akt1 cooperates with KRasG12D to accelerate in vivo pancreatic tumor onset and progression
WO2010033597A3 (fr) Procédés pour détecter une surexpression de sparc et procédés thérapeutiques et diagnostiques associés à ceux-ci
WO2013083098A3 (fr) Procédé de détermination de la sensibilité médicamenteuse de cellules cancéreuses aux inhibiteurs de l'aurora kinase
WO2012154567A3 (fr) Signature d'invasion humaine pour le pronostic d'un risque métastasique
WO2015057968A3 (fr) Méthodes pour identifier des sujets répondant au traitement d'une maladie auto-immune et compositions pour traiter ces sujets
WO2007124309A3 (fr) Procédés de détection de mutations de l'acide nucléique de jak2
Brunty et al. Peritoneal modulators of EZH2-miR-155 cross-talk in endometriosis
MX2009001070A (es) Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.
WO2011156249A3 (fr) Mesure de viabilité et de concentration de levures
WO2012166630A3 (fr) Système d'essai in vitro pour évaluer des xénobiotiques en tant qu'immunomodulateurs du transport et du métabolisme d'un médicament dans des hépatocytes humains
Hornsby Senescence and life span
WO2013066944A3 (fr) Biomarqueurs pour la caractérisation et le traitement du cancer
WO2011012764A3 (fr) Méthode d'identification de cellules souches mésenchymateuses sénescentes
WO2009126804A3 (fr) Expression de kir dans des cellules cancéreuses humaines en tant que biomarqueur d'un échappement à la réponse immune et de métastases du cancer
WO2010147452A8 (fr) Procédé pour l'évaluation d'un cancer dans un échantillon biologique obtenu à partir d'un sujet

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08755309

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 08755309

Country of ref document: EP

Kind code of ref document: A2